---
title: "Pliant Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285989685.md"
datetime: "2026-05-11T20:13:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285989685.md)
  - [en](https://longbridge.com/en/news/285989685.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285989685.md)
---

# Pliant Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.32, beating the estimate of USD -0.356.

EBIT: As of FY2026 Q1, the actual value is USD -21.77 M.

#### Financial Performance for the Three Months Ended March 31, 2026

-   **Research and Development (R&D) Expenses:** Pliant Therapeutics, Inc. reported R&D expenses of - $13.6 million for the first quarter of 2026, a decrease compared to - $43.4 million in the prior-year quarter, primarily due to the completion of close-out activities for the BEACON-IPF study in 2025 and reduced personnel-related expenses from decreased headcount.
-   **General and Administrative (G&A) Expenses:** G&A expenses were - $8.2 million for the first quarter of 2026, down from - $15.5 million in the prior-year quarter, mainly due to lower personnel-related expenses, including stock-based compensation, resulting from a reduced headcount.
-   **Net Loss:** The company’s net loss for the first quarter of 2026 was - $20.0 million, an improvement from a net loss of - $56.2 million in the prior-year quarter, driven by significantly lower operating expenses following the termination of bexotegrast development in IPF in 2025 and decreased personnel-related expenses.
-   **Interest and Other Income (Expense), Net:** Interest and other income (expense), net was $1.7 million in the first quarter of 2026, compared to $3.6 million in the prior-year quarter.
-   **Interest Expense:** There was no interest expense reported for the first quarter of 2026, compared to - $0.8 million in the prior-year quarter.

#### Financial Position as of March 31, 2026

-   **Cash, Cash Equivalents, and Short-Term Investments:** As of March 31, 2026, Pliant Therapeutics, Inc. held $172.4 million in cash, cash equivalents, and short-term investments, comprising $22.2 million in cash and cash equivalents and $148.7 million in short-term investments.
-   **Total Current Assets:** Total current assets were $174.9 million as of March 31, 2026, compared to $196.4 million as of December 31, 2025.
-   **Total Assets:** Total assets were $202.6 million as of March 31, 2026, down from $225.2 million as of December 31, 2025.
-   **Total Current Liabilities:** Total current liabilities were $10.4 million as of March 31, 2026, compared to $16.4 million as of December 31, 2025.
-   **Total Liabilities:** Total liabilities were $37.4 million as of March 31, 2026, compared to $44.0 million as of December 31, 2025.
-   **Total Stockholders’ Equity:** Total stockholders’ equity was $165.2 million as of March 31, 2026, compared to $181.2 million as of December 31, 2025.

#### Operational Highlights and Outlook

-   **Operational Metrics:** Pliant Therapeutics, Inc. initiated FORTIFY, a Phase 1b indication expansion trial for PLN-101095, ahead of schedule, with the first participant dosed in April 2026. The company continues to advance its proprietary integrin-targeted delivery platform with ongoing preclinical proof-of-concept studies.
-   **Financial Outlook:** Pliant Therapeutics, Inc. expects its $172.4 million in cash, cash equivalents, and short-term investments as of March 31, 2026, to be sufficient to fund operations into the second half of 2028.

### Related Stocks

- [PLRX.US](https://longbridge.com/en/quote/PLRX.US.md)

## Related News & Research

- [Pliant Therapeutics, Inc. $PLRX Stock Position Raised by ADAR1 Capital Management LLC](https://longbridge.com/en/news/294166622.md)
- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [Vale updates financial events calendar for 2026](https://longbridge.com/en/news/294418484.md)
- [Ciena's Q3 2026 Earnings: What to Expect](https://longbridge.com/en/news/293952665.md)
- [Equatorial Energia updates financial calendar for 2026 disclosures](https://longbridge.com/en/news/294368263.md)